Contact | Print version | PDF version | Send article | RSS feed

Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement

17 Jun 2009 - Cenix BioScience GmbH announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications. The new agreement calls for Cenix to complete at least three major projects applying the same leading platform for RNAi-based research that has now been utilized by major industry clients and partners in the EU and North America.
 
The work will integrate multi-pass genome-scale screens for the discovery of novel therapeutic target candidates with detailed validation analyses, all using a number of primary human cell types. Cenix will adapt assays initially developed by AstraZeneca scientists, combining several complementary technology platforms including automated microscopy with Cellenger-based image analysis, to optimize their implementation as high throughput RNAi studies in 384-well and/or 1,536-well formats.
 
Financial terms were not disclosed.